Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | REGN10597 |
| Synonyms | |
| Therapy Description |
REGN10597 is an immunocytokine comprising an anti-PDCD1 (PD-1) antibody fused to IL2Ra-masked IL-2, which potentially inhibits tumor growth (PMID: 39326410). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| REGN10597 | REGN 10597|REGN-10597 | REGN10597 is an immunocytokine comprising an anti-PDCD1 (PD-1) antibody fused to IL2Ra-masked IL-2, which potentially inhibits tumor growth (PMID: 39326410). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06413680 | Phase Ib/II | Cemiplimab + REGN10597 REGN10597 | A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body (BrILliance) | Recruiting | USA | 0 |